UEG's content platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

Re-live UEG Week 2026 on Gutflix Gut Guide online What's new on Gutflix

Trending on Gutflix

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

EFFECT OF DIETARY ANIMAL PROTEIN ON DEVELOPING GASTRIC CANCER CONSIDERING HELICOBACTER PYLORI: MULTI-CENTER PROSPECTIVE STUDY

Seong Woo Jeon 1, Su Youn Nam 1

Affiliations

1 Kyungpook National University, Daegu, Korea, Republic of

Summary

AI Generated

A prospective study of 5,535 subjects found that dietary animal proteins showed non-linear or positive associations with gastric cancer risk after adjusting for Helicobacter pylori status.

Red meat, fish, and eggs demonstrated U-shaped associations with gastric cancer, with optimal intake at 2 servings per week for red meat, 1 serving per week for fish, and 2-3 servings per week for eggs.
High intake of processed meat was associated with increased gastric cancer risk (adjusted odds ratio 1.78, 95% CI 1.27-2.49).
White meat intake showed a dose-dependent positive association with gastric cancer risk, with adjusted odds ratios ranging from 1.67 for 1 serving per week to 4.16 for 3 or more servings per week.
The associations between animal protein intake and gastric cancer persisted after adjusting for Helicobacter pylori status and were similar in both men and women.
This material may be relevant to gastroenterologists and epidemiologists interested in dietary risk factors for gastric cancer.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Dietary animal protein effect on gastric cancer (GC) taking Helicobacter pylori status into account has rarely been reported and has therefore been investigated in this study.

Aims & Methods

GC patients and healthy subjects were prospectively registered by 6 hospitals from October 2016 to December 2018. Multivariate analysis adjusted for many epidemiological factors (Model I) and additionally H. pylori (Model II) was conducted to investigate dietary protein effect on GC. Dietary animal protein groups included red meat, processed meat, white meat, eggs, and fishes.

Results

A total of 5,535 subjects (1,629 GCs) were enrolled. In Model I, red meat, fish, and eggs showed non-linear associations. Two serving/week for red meat, 1 serving/week for fish, 2-3 serving /week for egg was associated with the lowest risk of GC. Both low (aOR, 1.33) and high intake (aOR, 1.49) of red meat were associated with increased risk of GC. Both low (aOR, 1.76) and high intake (aOR, 1.74) of fish were associated with increased risk of GC. Both low (aOR, 3.07) and high intake (aOR, 1.33) of egg were associated with increased risk of GC. High intake of processed meat was associated with GC (adjusted odd ratio [aOR], 1.78; 95% CI, 1.27-2.49). Frequent intake of white meat was associated with GC risk (aOR, 1.67 for 1 serving/week, 2.15 for 2 servings/week, and 4.16 for ≥3 servings/week). In model II, these non-linear or positive association were sustained. Sub-analysis by sex showed similar association in both men and women.

Conclusion

Dietary animal proteins had non-linear or positive association with GC after adjusted for H. pylori. Nonlinear relationships of some food groups with GC suggests modest intake of such foods may reduce GC risk.

Disclosure

No COI

Conference

UEG Week Vienna 2024

Topics

Oesophagus

Submission format

Abstract

Session

OESOPHAGEAL, GASTRIC AND DUODENAL (Posters)

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

More Like This:

Episode 7: UEG Journal Podcast Christmas Special

Daniel Keszthelyi

CD4+ T CELL TRANSCRIPTOMIC, EPIGENETIC AND CLONAL PROFILES IN MONOZYGOTIC TWINS REFLECT SHARED HOST IMPRINTING RATHER THAN CROHN’S DISEASE STATUS

Femke van Wijk

EVALUATION OF CHANGES IN GENE EXPRESSION IN COLONIC BIOPSY SAMPLES FROM PATIENTS TREATED WITH AFIMKIBART IN THE TUSCANY-2 TRIAL

Domagoj Vucic

NEOPLASIA DETECTION RATES IN IBD SURVEILLANCE

Jóhann Hreinsson

PELVIMETRY AS A PREDICTIVE FACTOR FOR POSTOPERATIVE OUTCOMES AND INTRAOPERATIVE SURGICAL COMPLEXITY IN ILEAL POUCH-ANAL ANASTOMOSIS

Valerio Celentano

Acting upstream in the pathophysiological cascade of ascites and managing recurrent ascites and its consequences: From TAPS to TIPS

Pere Ginès

UEG Podcast Episode

Journal Podcast

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Episode 7: UEG Journal Podcast Christmas Special

Albrecht Neesse, Daniel Keszthelyi

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Topics

Primary Care

Published

2025

More Like This:

Episode 7: UEG Journal Podcast Christmas Special

Daniel Keszthelyi

CD4+ T CELL TRANSCRIPTOMIC, EPIGENETIC AND CLONAL PROFILES IN MONOZYGOTIC TWINS REFLECT SHARED HOST IMPRINTING RATHER THAN CROHN’S DISEASE STATUS

Femke van Wijk

EVALUATION OF CHANGES IN GENE EXPRESSION IN COLONIC BIOPSY SAMPLES FROM PATIENTS TREATED WITH AFIMKIBART IN THE TUSCANY-2 TRIAL

Domagoj Vucic

NEOPLASIA DETECTION RATES IN IBD SURVEILLANCE

Jóhann Hreinsson

PELVIMETRY AS A PREDICTIVE FACTOR FOR POSTOPERATIVE OUTCOMES AND INTRAOPERATIVE SURGICAL COMPLEXITY IN ILEAL POUCH-ANAL ANASTOMOSIS

Valerio Celentano

Acting upstream in the pathophysiological cascade of ascites and managing recurrent ascites and its consequences: From TAPS to TIPS

Pere Ginès

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

CD4+ T CELL TRANSCRIPTOMIC, EPIGENETIC AND CLONAL PROFILES IN MONOZYGOTIC TWINS REFLECT SHARED HOST IMPRINTING RATHER THAN CROHN’S DISEASE STATUS

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

CD4+ T CELL TRANSCRIPTOMIC, EPIGENETIC AND CLONAL PROFILES IN MONOZYGOTIC TWINS REFLECT SHARED HOST IMPRINTING RATHER THAN CROHN’S DISEASE STATUS

Thom Kusters 1, Eelco C. Brand 1, Elise Saager 1, Sarah Dijkstra 1, Jonas Louwers 1, Sophie Bakker 1, Leonie Holland-van den Noort 1, Theo van den Broek 1, Alex Yermanos 1,2, Bas Oldenburg 1, Femke van Wijk 1

Affiliations

1 University Medical Centre Utrecht, Utrecht, Netherlands

2 Botnar Institute of Immune Engineering, Basel, Switzerland

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Crohn's disease (CD) is thought to result from complex interactions between genetic susceptibility, environmental factors, gut dysbiosis, and aberrant immune activation, in which CD4+ T helper cells play a central pathogenic role. Monozygotic twins provide a unique model to investigate disease-associated immune alterations while controlling for genetic background and (early-life) environmental exposures. Moreover, unaffected co-twins of CD-discordant pairs are at increased risk of developing CD, offering an opportunity to study potential preclinical immune signatures.

Aims & Methods

We compared peripheral CD4+ T cell profiles in monozygotic twins from the IBD-TWIN cohort¹ and unrelated healthy controls. Single-cell RNA sequencing with paired T-cell receptor (TCR) profiling was performed on naive and gut-homing (integrin β7+) memory CD4+ T cell subsets from CD-concordant (n=4) and CD-discordant (n=4) monozygotic twin pairs, as well as unrelated healthy controls (n=4). DNA methylation profiling was performed on gut-homing memory and both gut- and non-gut-homing naive CD4+ T cells from CD-concordant (n=2) and CD-discordant (n=9) monozygotic twin pairs and healthy controls (n=11).

Results

Transcriptomes and methylomes of naive and gut-homing memory CD4+ T cells were highly similar between monozygotic co-twins irrespective of disease concordance, whereas both affected and unaffected co-twins differed from unrelated healthy controls. In addition, TCR repertoires of co-twins displayed greater overlap in paired αβ complementarity-determining region 3 (CDR3) sequences compared to unrelated individuals.

Conclusion

CD4+ T cell profiles and repertoires appear strongly shaped by shared host-related factors, including genetics and (early-life) environment, whereas disease concordance had limited impact on transcriptional, epigenetic and clonal profiles.

References

Brand, E. C., Klaassen, M. A., Gacesa, R., Vila, A. V., Ghosh, H., De Zoete, M. R., ... & Oldenburg B, Weersma RK. Healthy cotwins share gut microbiome signatures with their inflammatory bowel disease twins and unrelated patients. Gastroenterology. 2021;160(6):1970-1985.

Disclosure

Dr E.C. Brand was co-applicant on an unrestricted Investigator Initiated Research Grant of Pfizer
Prof. B Oldenburg: unrestricted grants: Abbvie, Takeda, Pfizer, Galapagos Advisory boards: Abbvie, Takeda, Pfizer, Lilly, Galapagos, Janssen
Prof. F. van Wijk: has been a speaker and/or consultant for Janssen, Johnson & Johnson, and Takeda and has received grants fromRegeneron Pharmaceuticals, Leo Pharma, Sanofi, BMS, Galapagos, and Takeda.

Event

UEG Week Barcelona 2026

Topics

Histopathology Surgery Radiology & Imaging Mechanisms & Personalised Medicine Immunology IBD

Submission format

Late-Breaking Abstract

Session

Late-Breaking in IBD: From translational discoveries to treatment

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Episode 7: UEG Journal Podcast Christmas Special

Daniel Keszthelyi

CD4+ T CELL TRANSCRIPTOMIC, EPIGENETIC AND CLONAL PROFILES IN MONOZYGOTIC TWINS REFLECT SHARED HOST IMPRINTING RATHER THAN CROHN’S DISEASE STATUS

Femke van Wijk

EVALUATION OF CHANGES IN GENE EXPRESSION IN COLONIC BIOPSY SAMPLES FROM PATIENTS TREATED WITH AFIMKIBART IN THE TUSCANY-2 TRIAL

Domagoj Vucic

NEOPLASIA DETECTION RATES IN IBD SURVEILLANCE

Jóhann Hreinsson

PELVIMETRY AS A PREDICTIVE FACTOR FOR POSTOPERATIVE OUTCOMES AND INTRAOPERATIVE SURGICAL COMPLEXITY IN ILEAL POUCH-ANAL ANASTOMOSIS

Valerio Celentano

Acting upstream in the pathophysiological cascade of ascites and managing recurrent ascites and its consequences: From TAPS to TIPS

Pere Ginès

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

EVALUATION OF CHANGES IN GENE EXPRESSION IN COLONIC BIOPSY SAMPLES FROM PATIENTS TREATED WITH AFIMKIBART IN THE TUSCANY-2 TRIAL

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

EVALUATION OF CHANGES IN GENE EXPRESSION IN COLONIC BIOPSY SAMPLES FROM PATIENTS TREATED WITH AFIMKIBART IN THE TUSCANY-2 TRIAL

Luis Quintanilla 1, Mouly Rahman 2, Franklin Fuh 1, Meng Sun 1, Ephraim Kenigsberg 1, Domagoj Vucic 1, Shadi Toghi Eshghi 1, Sharmila Chatterjee 1, Priyanka Kulkarni 1, Judit Jané Valbuena 1, Michal Slyper Biton 1, Anindita Banerjee 3, Deepa E. Chandra 3, Elena Peeva 3, Srividya Neelakantan 3, Michael S. Vincent 3, Vishnu Mohanan 2, Margaret Neighbors 1

Affiliations

1 Genentech, Inc., South San Francisco, United States

2 F. Hoffmann‑La Roche Ltd., Basel, Switzerland

3 Pfizer Inc., Cambridge, United States

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Tumour necrosis factor-like ligand 1A (TL1A) and its signalling receptor, death receptor 3 (DR3), have been implicated in the pathogenesis of inflammatory bowel disease (IBD) through effects on both immune and tissue-resident cells.^1-5 In TUSCANY-2 (NCT04090411), a double-blind, randomised, phase 2b trial, adults with moderately to severely active ulcerative colitis (UC) treated with the anti-TL1A antibody afimkibart showed a positive benefit-risk profile compared with placebo.⁶ Here, we assessed cell-specific changes in TL1A pathway gene expression in colonic tissue collected in TUSCANY-2 to define pharmacodynamic effects and provide mechanistic insights into the mode of action of afimkibart at the cellular level.

Aims & Methods

Colonic pinch biopsy samples were measured from patients in the afimkibart 450 mg (n=58) and placebo (n=28) arms of the TUSCANY-2 trial at screening and week 14. Single nucleus RNA sequencing (10X Genomics FLEX snRNAseq) analysis was performed to characterise changes in gene expression, cellular abundance, and pathways across colonic cell populations. A TL1A-responsive CD4 T-cell gene expression signature was used as a pharmacodynamic measure of target engagement.

Results

The snRNAseq dataset captured multiple relevant mucosal cell types. Consistent with prior biology, TL1A was highly expressed in monocytes, macrophages, and fibroblasts; DR3 was expressed in innate lymphoid, T helper 17 (Th17), CD4+, T regulatory, and endothelial cells. The TL1A decoy receptor DcR3 was highly expressed in enterocytes, endothelial cells, and fibroblasts. A TL1A-responsive CD4 T-cell gene expression signature was significantly inhibited (p=0.0000252) in CD4 T-cells from screening to week 14 with afimkibart treatment, but not placebo. In addition, samples from afimkibart-treated patients showed broad transcriptomic changes across multiple cellular lineages, particularly epithelial, myeloid, fibroblast, and T-cell lineages, whereas very few changes in gene expression were observed in the placebo group, indicating that TL1A blockade influences gene expression beyond immune cell populations, including epithelial and stromal compartments. Pathway analysis within CD4 T-cells showed decreases in cellular division post-treatment, consistent with reductions observed in T-cell lineage abundance at week 14 in the afimkibart arm.

Conclusion

This is the first interventional trial in this class to assess TL1A blockade at single-cell resolution in colonic tissue. Afimkibart induced complete target inhibition in the tissue and broad transcriptional changes across immune and tissue-resident mucosal populations, including cell types without prominent DR3 expression. These findings support a mode of action that extends beyond suppression of inflammation to modulation of dysregulated epithelial and stromal/fibrotic tissue programmes after TL1A blockade.

References

¹Bamias G, et al. Gut. 2025;74(4):652–668.
²Xu W-D, et al. Front Immunol. 2022;13:891328.
³Pappu BP, et al. J Exp Med. 2008;205(5):1049–1062.
⁴Wang S, et al. Front Immunol. 2024;15:1340467.
⁵Solitano V, et al. Med. 2024;5(5):386–400.
⁶Danese S, et al. Lancet Gastroenterol Hepatol. 2025;10:882-95.

Disclosure

Funded by F. Hoffmann-La Roche, Ltd

Event

UEG Week Barcelona 2026

Topics

Mechanisms & Personalised Medicine IBD

Submission format

Abstract

Session

Looking at the small details: Lessons from sub-studies of clinical trials in IBD

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Episode 7: UEG Journal Podcast Christmas Special

Daniel Keszthelyi

CD4+ T CELL TRANSCRIPTOMIC, EPIGENETIC AND CLONAL PROFILES IN MONOZYGOTIC TWINS REFLECT SHARED HOST IMPRINTING RATHER THAN CROHN’S DISEASE STATUS

Femke van Wijk

EVALUATION OF CHANGES IN GENE EXPRESSION IN COLONIC BIOPSY SAMPLES FROM PATIENTS TREATED WITH AFIMKIBART IN THE TUSCANY-2 TRIAL

Domagoj Vucic

NEOPLASIA DETECTION RATES IN IBD SURVEILLANCE

Jóhann Hreinsson

PELVIMETRY AS A PREDICTIVE FACTOR FOR POSTOPERATIVE OUTCOMES AND INTRAOPERATIVE SURGICAL COMPLEXITY IN ILEAL POUCH-ANAL ANASTOMOSIS

Valerio Celentano

Acting upstream in the pathophysiological cascade of ascites and managing recurrent ascites and its consequences: From TAPS to TIPS

Pere Ginès

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

NEOPLASIA DETECTION RATES IN IBD SURVEILLANCE

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

NEOPLASIA DETECTION RATES IN IBD SURVEILLANCE

Arvin Lashgarara 1,2, Johannes Blom 3,4, Peter Thelin Schmidt 5, Anna Forsberg 6, Jóhann Hreinsson 1,2

Affiliations

1 Sahlgrenska University Hospital, Gothenburg, Sweden

2 Gothenburg University, Sahlgrenska Academy, Institute of Medicine, Gothenburg, Sweden

3 Södersjukhuset, Stockholm, Sweden

4 Karolinska Institutet, Stockholm, Sweden

5 Uppsala University Hospital, Uppsala University, Uppsala, Sweden

6 Karolinska Institutet, Institute of Medicine, Stockholm, Sweden

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

In inflammatory bowel disease (IBD) surveillance, current ESGE guidelines recommend a minimum neoplasia detection rate (NDR) of >8%, whilst desirable detection rates have not been defined.¹These recommendations, however, are based on a limited number of studies, predominantly carried out in academic referral centres.

Aims & Methods

We aimed to evaluate NDR in IBD surveillance at a nationwide level, assessing performance across all endoscopists to determine whether existing detection rate thresholds should potentially be adjusted. Furthermore, to assess if conventional adenoma detection rate (ADR) in colorectal cancer screening correlates with NDR in IBD surveillance. We utilized data from the Swedish Registry for Colorectal Cancer Screening and Colonoscopy (SveReKKS), a prospectively entered, web-based national register. Data were retrieved for the period April 2019 to October 2025. Variables extracted from the registry included indication for colonoscopy, bowel preparation, ileocecal intubation, presence of suspected malignancy, polyp detection, biopsy or removal of polyp, and corresponding histopathological results. Neoplasia detection was defined as dysplasia in lesions that were removed or biopsied. Data were not available for lesions that were not classified as polyps or cancer in the registry, nor for cases of “invisible” dysplasia (i.e., dysplasia in random biopsies). Adequate bowel preparation was defined as Boston Bowel Preparation Scale score >6 in total, with an individual segment score of ≥2.

Results

In total, 8,757 IBD surveillance colonoscopies were performed by 333 endoscopists. After excluding endoscopists that had registered less than 50 IBD surveillance colonoscopies, 3,386 endoscopies and 40 endoscopists remained. The mean age of the patients in the cohort was 53 (SD 15) years and 58% were male. Bowel preparation was adequate in 95% of colonoscopies and ileocecal intubation was achieved in 97%. The overall NDR was 8.8% (95% CI 7.9, 9.8%), and cancer detection rate was 0.15% (95% CI 0.05, 0.34%). Endoscopist-specific NDR ranged from 0.8% to 21.8%, with substantial variation across NDR quintiles (Table 1). The second-highest quintile (60–80%) and highest quintile (80–100%) of endoscopists had detection rates of 9.6–13.0% and 13.2–21.8%, respectively. Overall, 22 endoscopists registered more than 50 colonoscopies for both colorectal cancer screening and IBD surveillance. Among these endoscopists, adenoma detection rate (ADR) and NDR demonstrated a moderate-to-strong correlation (R² = 0.59; β = 0.37 [95% CI 0.23–0.52]). A higher ADR was associated with a NDS, each 10 percentage-point increase in ADR corresponded to an estimated 3.7 percentage-point increase in NDR (95% CI 2.3 to 5.2). However, among endoscopists with a NDR <8%, ADR still ranged widely from 32% to 58%.

NDR quintile	NDR range (%)	NDR (95CI) (%)	ADR (95CI) (%)
20–40%	3.7–5.6	4.9 (2.8–8.3)	39.7 (33.8–45.9)
40–60%	6.0–9.4	8.3 (6.1–11.2)	57.5 (52.9–62.0)
60–80%	10.1–11.3	10.8 (7.3–15.9)	59.1 (52.2–65.6)
80–100%	13.0–21.8	15.8 (13.0–19.1)	67.0 (63.0–70.7)

Conclusion

These results indicate that the current European guidelines for NDR in IBD surveillance seem reasonable, however, higher detection rates can be achieved. Therefore, raising the minimum NDR threshold in IBD surveillance, and setting desirable thresholds, can be considered. Furthermore, although a high ADR in colorectal cancer screening correlated with NDR, this correlation was not absolute, suggesting that deidicated training in neoplasia detection in IBD surveillance may be required.

References

1. Dekker E et al. Performance measures for colonoscopy in inflammatory bowel disease patients: European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy. 2022 Sep;54(9):904-915. doi: 10.1055/a-1874-0946. Epub 2022 Jul 29. PMID: 35913069.

Event

UEG Week Barcelona 2026

Topics

Colorectal IBD

Submission format

Abstract

Session

IBD diagnostics: In search of optimal implementation

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Episode 7: UEG Journal Podcast Christmas Special

Daniel Keszthelyi

CD4+ T CELL TRANSCRIPTOMIC, EPIGENETIC AND CLONAL PROFILES IN MONOZYGOTIC TWINS REFLECT SHARED HOST IMPRINTING RATHER THAN CROHN’S DISEASE STATUS

Femke van Wijk

EVALUATION OF CHANGES IN GENE EXPRESSION IN COLONIC BIOPSY SAMPLES FROM PATIENTS TREATED WITH AFIMKIBART IN THE TUSCANY-2 TRIAL

Domagoj Vucic

NEOPLASIA DETECTION RATES IN IBD SURVEILLANCE

Jóhann Hreinsson

PELVIMETRY AS A PREDICTIVE FACTOR FOR POSTOPERATIVE OUTCOMES AND INTRAOPERATIVE SURGICAL COMPLEXITY IN ILEAL POUCH-ANAL ANASTOMOSIS

Valerio Celentano

Acting upstream in the pathophysiological cascade of ascites and managing recurrent ascites and its consequences: From TAPS to TIPS

Pere Ginès

UEG Poster

New

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

PELVIMETRY AS A PREDICTIVE FACTOR FOR POSTOPERATIVE OUTCOMES AND INTRAOPERATIVE SURGICAL COMPLEXITY IN ILEAL POUCH-ANAL ANASTOMOSIS

Carlo Alberto Manzo 1, Silvia Perez Ajates 2, Mahmood Humza 3, Mariano Giglio 4, Yu Jin Lee 3, Triantafyllos Doulias 5, Gianluca M Sampietro 6, Valerio Celentano 3

Affiliations

1 ASST Rhodense - Ospedale di Rho, Rho, Italy

2 Gregorio Marañón General University Hospital, Madrid, Spain

3 Chelsea and Westminster Hospital, London, United Kingdom

4 Università Federico II, Naples, Italy

5 Kettering General Hospital NHS Foundation Trust, Kettering, United Kingdom

6 ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco Polo Universitario, Milano, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Ileal pouch-anal anastomosis (IPAA) is a technically demanding procedure for Ulcerative Colitis (UC), and preoperative tools to predict surgical difficulty remain limited. This study aimed primarily to evaluate the correlation between preoperative pelvimetric parameters and postoperative outcomes, while exploring their association with intraoperative surgical difficulty in IPAA.

Aims & Methods

A retrospective, single-centre cohort study was conducted including 56 patients who underwent primary IPAA for UC between 2021 and 2024. Pelvimetric measurements were obtained from preoperative MRI or CT scans, normalized to body surface area (BSA), and correlated with postoperative outcomes and intraoperative surgical difficulty using univariate analysis.

Results

The median BSA-normalized measurements were: pelvic inlet 66.7 mm, pelvic outlet 48.1 mm, and pelvic depth 57.4 mm. A longer normalized S3–coccyx distance and greater pelvic depth were significantly associated with increased pelvic sepsis (p=0.003). The normalized S3–coccyx distance also correlated with a higher rate of pouchitis at one year (p=0.009). A wider interacetabular distance, reflecting pelvic width, was associated with greater intraoperative surgical complexity (p=0.007). No pelvimetric variable correlated with overall postoperative complications or functional outcomes.

Conclusion

Specific pelvimetric parameters, particularly pelvic depth and width, are associated with an increased risk of septic complications and greater intraoperative surgical complexity in IPAA. Incorporating preoperative pelvimetry into routine assessment may enhance risk stratification and inform surgical planning. Larger, multicentre studies are warranted to validate these findings and refine patient selection for restorative proctocolectomy.

Conference

UEG Week Barcelona 2026

Topics

IBD

Submission format

Abstract

Session

IBD (INCLUDING MICROSCOPIC COLITIS) (Posters)

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Episode 7: UEG Journal Podcast Christmas Special

Daniel Keszthelyi

CD4+ T CELL TRANSCRIPTOMIC, EPIGENETIC AND CLONAL PROFILES IN MONOZYGOTIC TWINS REFLECT SHARED HOST IMPRINTING RATHER THAN CROHN’S DISEASE STATUS

Femke van Wijk

EVALUATION OF CHANGES IN GENE EXPRESSION IN COLONIC BIOPSY SAMPLES FROM PATIENTS TREATED WITH AFIMKIBART IN THE TUSCANY-2 TRIAL

Domagoj Vucic

NEOPLASIA DETECTION RATES IN IBD SURVEILLANCE

Jóhann Hreinsson

PELVIMETRY AS A PREDICTIVE FACTOR FOR POSTOPERATIVE OUTCOMES AND INTRAOPERATIVE SURGICAL COMPLEXITY IN ILEAL POUCH-ANAL ANASTOMOSIS

Valerio Celentano

Acting upstream in the pathophysiological cascade of ascites and managing recurrent ascites and its consequences: From TAPS to TIPS

Pere Ginès

UEG Presentation

New

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Acting upstream in the pathophysiological cascade of ascites and managing recurrent ascites and its consequences: From TAPS to TIPS

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Acting upstream in the pathophysiological cascade of ascites and managing recurrent ascites and its consequences: From TAPS to TIPS

Salvatore Piano 1, Pere Ginès 2

Affiliations

1 University of Padova, Padova, Italy

2 CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER, Barcelona, Spain

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

Postgraduate Teaching Programme Barcelona 2026

Session

Advanced chronic liver disease: When the liver gets stiff, the complications get going

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

Episode 7: UEG Journal Podcast Christmas Special

Daniel Keszthelyi

CD4+ T CELL TRANSCRIPTOMIC, EPIGENETIC AND CLONAL PROFILES IN MONOZYGOTIC TWINS REFLECT SHARED HOST IMPRINTING RATHER THAN CROHN’S DISEASE STATUS

Femke van Wijk

EVALUATION OF CHANGES IN GENE EXPRESSION IN COLONIC BIOPSY SAMPLES FROM PATIENTS TREATED WITH AFIMKIBART IN THE TUSCANY-2 TRIAL

Domagoj Vucic

NEOPLASIA DETECTION RATES IN IBD SURVEILLANCE

Jóhann Hreinsson

PELVIMETRY AS A PREDICTIVE FACTOR FOR POSTOPERATIVE OUTCOMES AND INTRAOPERATIVE SURGICAL COMPLEXITY IN ILEAL POUCH-ANAL ANASTOMOSIS

Valerio Celentano

Acting upstream in the pathophysiological cascade of ascites and managing recurrent ascites and its consequences: From TAPS to TIPS

Pere Ginès